It’s the Deadliest Cancer for Australian Men. This Test Could Be Life-Saving for Many, and Their Daughters Prostate cancer remains the most commonly diagnosed cancer and the second leading cause of cancer death among Australian men, claiming over 3,500 lives each year. While survival rates have improved due to advances in treatment and early detection, disparities in screening access and awareness continue to impact outcomes—particularly for men in regional and remote areas, and those with a family history of the disease. Emerging evidence highlights that a simple, accessible test could significantly improve early detection rates, potentially saving lives not only for men but too informing risk assessment for their female relatives. The Prostate-Specific Antigen (PSA) test, a blood test that measures levels of a protein produced by the prostate gland, has long been central to prostate cancer screening discussions. Although controversial in the past due to concerns about overdiagnosis and overtreatment of slow-growing tumors, recent guidelines from leading health organizations now support informed, shared decision-making about PSA testing—especially for men at higher risk. According to the Cancer Council Australia, men aged 50 to 69 should discuss the benefits and risks of PSA testing with their doctor. For those with a family history of prostate cancer—particularly if a father or brother was diagnosed before age 60—or for men of African descent, this conversation should begin at age 45. The test itself is quick, minimally invasive, and widely available through general practitioners and pathology services across Australia. Research published in the Medical Journal of Australia shows that organized screening programs incorporating PSA testing, followed by multiparametric MRI when indicated, can reduce prostate cancer mortality by up to 20% in screened populations. A 2023 study from the Garvan Institute of Medical Research found that men with elevated PSA levels who underwent timely follow-up were significantly more likely to have cancer detected at a localized, treatable stage. Importantly, implications of prostate cancer screening extend beyond male patients. Inherited genetic mutations—such as those in the BRCA2 gene—are linked not only to increased prostate cancer risk in men but also to higher risks of breast, ovarian, and pancreatic cancer in female relatives. A study in the Journal of Clinical Oncology revealed that men with BRCA2 mutations face up to an eightfold increase in prostate cancer risk and tend to develop more aggressive forms of the disease. Oncologists now recommend that men diagnosed with prostate cancer, especially those with early-onset or high-grade tumors, undergo genetic counseling, and testing. Findings can then inform screening and prevention strategies for their daughters and sisters. Professor Rodney Mitchell, a medical oncologist at Peter MacCallum Cancer Centre in Melbourne, emphasizes: “When we identify a genetic link in a man with prostate cancer, it’s not just about his treatment—it’s an opportunity to protect his family. Daughters of men with BRCA mutations may benefit from earlier breast cancer screening or preventive measures, turning a cancer diagnosis into a proactive health opportunity for the next generation.” Despite these advances, barriers remain. A 2022 survey by the Prostate Cancer Foundation of Australia found that nearly 40% of Australian men had never discussed prostate cancer screening with their GP, and awareness was lowest among younger men and those from culturally and linguistically diverse backgrounds. Efforts to improve outreach—including targeted campaigns in community health centers, Indigenous health services, and workplace wellness programs—are underway to close this gap. Innovations in diagnostic accuracy are also reducing unnecessary biopsies. The use of MRI before biopsy has grow standard in many Australian hospitals, helping distinguish between aggressive cancers requiring treatment and low-risk tumors suitable for active surveillance. This approach minimizes overtreatment while ensuring that significant cancers are not missed. For men considering screening, experts recommend: – Starting conversations about prostate cancer risk at age 45 if there’s a family history or other risk factors. – Discussing PSA testing benefits and limitations with a healthcare provider. – Considering follow-up MRI if PSA levels are elevated, rather than proceeding directly to biopsy. – Exploring genetic testing if diagnosed with prostate cancer, particularly if there’s a family history of cancer or early-onset disease. While no screening test is perfect, the PSA test—when used thoughtfully within an individualized risk assessment—remains one of the most effective tools available to reduce prostate cancer mortality in Australia. For men, it offers a chance at early detection and less invasive treatment. For their daughters, it may reveal hereditary risks that empower earlier intervention and prevention. As research continues to refine screening strategies and genetic insights grow, the message is clear: talking about prostate cancer isn’t just about men’s health. It’s a family conversation that could save lives across generations.
18
previous post